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ABSTRACT
A number of pharmacogenetic studies have been carried out in non-small-cell 
lung cancer (NSCLC) to identify and characterize genes involved in chemotherapy 
activity. However, the results obtained so far are controversial and no reliable 
biomarker is currently used to predict clinical benefit from platinum-based 
chemotherapy, which represents the cornerstone of treatment of advanced NSCLC. 
This study investigated the expression levels of ERCC1 and of six genes (RRM1, RRM2, 
hENT1, dCK, cN-II and CDA) involved in gemcitabine metabolism in locally/advanced 
NSCLC patients treated with gemcitabine/platinum combination. Gene expression 
was assessed by quantitative-PCR in laser-microdissected specimens and correlated 
with tumor response. Frequency distribution of responses above and below the 
median expression level of biomarkers was compared using a two-sided Fisher’s 
test. 5′-nucleotidase (cN-II) was the only gene differently expressed (p = 0.016) in 
the responders (complete/partial-response) compared to non-responders (stable/
progressive disease). In the multivariate analysis, overexpression of this catabolic 
enzyme of gemcitabine remained a significant negative predictive factor. Patients 
www.oncotarget.com                                           Oncotarget, 2018, Vol. 9, (No. 23), pp: 16437-16450
                                                   Research Paper
Oncotarget16438www.oncotarget.com
INTRODUCTION
Over one million people worldwide die every year 
due to lung cancer, making it the leading cause of cancer-
related deaths [1]. Non-small-cell lung cancer (NSCLC) 
accounts for approximately 85% of all lung cancer cases. 
Only a minority of patients are diagnosed with localized, 
early-stage disease for which the optimal treatment 
remains surgical resection, lobectomy or pneumonectomy, 
with curative intent, followed by adjuvant chemotherapy, 
when indicated [2–4]. In most patients NSCLC presents 
at diagnosis as a locally advanced or metastatic disease. 
A number of patients with locally advanced disease can 
undergo surgery following induction chemotherapy, but 
most cases are definitely treated with chemotherapy, 
such as the metastatic patients [5]. In recent years, 
the treatment of metastatic NSCLC patients has been 
revolutionized by the introduction of new therapeutic 
agents specifically designed to target somatically 
activated oncogenes, such as mutant EGFR and rearranged 
ALK [6–8]. However, only relatively small subgroups 
of patients, mainly with adenocarcinoma histology, 
derive benefit from these targeted therapies. Moreover, 
despite initial remarkable responses to EGFR or ALK 
tyrosine kinase inhibitors, almost all patients progress 
due to acquired drug resistance [9]. For those patients 
without any targetable driver mutations, platinum-based 
chemotherapy represents the standard of care. However, 
cytotoxic chemotherapy is burdened by an unsatisfactory 
response rate, which is less than 30% irrespective of the 
drug combination regimen administered, and offers only 
a modest improvement of survival, which still remains 
poor for these patients. The response to treatment is  also 
characterized by large inter-patient variability. So far, a 
number of studies have evaluated the predictive value of 
different biomarkers, and several genetic and epigenetic 
alterations, including gene mutations, gene amplification, 
single nucleotide polymorphisms or altered gene/protein 
expression, have been associated with treatment outcome 
to chemotherapy in NSCLC [10–13]. However, most 
data on possible predictors of response are inconclusive 
suggesting that pharmacogenetic associations may not 
always be reproducible when focusing on single candidate 
biomarkers explored in small size series, without 
standardized unbiased methods, as well as in different 
settings for tumor type, stage and evaluation of treatment 
outcome [13, 14]. Further studies integrating different 
candidate biomarkers in homogeneous populations, with 
standardized methods and objective parameters for the 
evaluation of drug activity are urgently warranted.
Most previous biomarkers studies in NSCLC have 
focused on key enzymes of the Nucleotide Excision 
Repair (NER) pathway, such as ERCC1, which can 
remove bulky adducts and intrastrand crosslinks by 
platinum-compounds and thus modulate response to these 
cytotoxic drugs [15, 16]. Indeed, ERCC1 expression levels 
have been variably associated with response to cisplatin-
based chemotherapy and survival in patients with NSCLC 
in several retrospective studies [17, 18]. 
Fewer studies evaluated molecular determinants of 
gemcitabine activity. Gemcitabine (difluorodeoxycytidine; 
dFdC) is a deoxycytidine analogue whose metabolism 
parallels that of arabinofuranosylcytosine (AraC), but 
has a distinct mechanism of action [19]. Because of its 
hydrophilicity, gemcitabine does not cross the membrane 
by diffusion and it is transported into cells mostly by the 
human equilibrative nucleoside transporter 1 (hENT1). 
A deficiency of this transporter has been associated with 
drug resistance in in vitro studies [19, 20] and in pancreatic 
cancer patients [21]. Following cellular uptake, gemcitabine 
requires intracellular phosphorylation to produce active 
diphosphate (dFdCDP) and triphosphate (dFdCTP) forms 
that act by inhibiting the enzyme ribonucleotide reductase 
(RR) and DNA synthesis, respectively. Deoxycytidine 
kinase (dCK) is the rate-limiting enzyme in this 
biotransformation and its deficiency has been associated 
with resistance to gemcitabine in NSCLC cells [19] and 
in tumor xenografts [22] but no association with clinical 
outcome was observed in patients with NSCLC treated with 
gemcitabine-based chemotherapy [23]. 
Some other studies have evidenced an association 
between disease response and mRNA levels of the 
ribonucleotide reductase regulatory subunit (RRM1). 
Ribonucleotide reductase is a key enzyme for DNA synthesis, 
is involved in DNA repair and gemcitabine metabolism and 
overexpression of RRM1 was associated with gemcitabine 
resistance in NSCLC cell lines [24]. In stage III-IV NSCLC 
patients treated with gemcitabine/cisplatin a high RRM1 
expression was related to a poor outcome [17, 25–27].
Cytidine deaminase (CDA) and cytoplasmic 
5′-nucleotidase II (cN-II) are considered the major 
gemcitabine inactivation enzymes. Their crucial role 
with low cN-II had a modest trend toward increased survival, while both survival and 
progression-free survival were significantly longer in a more homogenous validation 
cohort of 40 advanced NSCLC (8.0 vs. 5.1 months, p = 0.026). Moreover, in vitro 
studies showed that silencing or pharmacological inhibition of cN-II increased the 
cytotoxicity of gemcitabine. This is the first study demonstrating the role of cN-II as a 
predictor of response to gemcitabine/platinum combinations in NSCLC. Its validation 
in prospective studies may improve clinical outcome of selected patients.
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was demonstrated in in vitro experiments by modulating 
their activity with specific inhibitors [28]. Resistance to 
gemcitabine has been demonstrated in cells overexpressing 
CDA in vitro [19]. However, the role of CDA may be more 
important in the pharmacokinetics of gemcitabine, since 
a high systemic CDA level was associated with a poor 
efficacy and a low CDA levels with increased, sometime 
lethal toxicity [29]. cN-II levels were significantly 
lower in patients with chronic lymphocytic B-leukemia 
responsive to cladribine than in non-responders [30]. cN-
II expression has been considered as a new potential target 
[31], but might also be an independent prognostic factor in 
patients with NSCLC treated with gemcitabine, with lower 
levels associated with a poor prognosis [23]. 
Based on the above evidence, we evaluated the 
intratumoral expression of ERCC1, RRM1, RRM2, 
hENT1, dCK, cN-II and CDA (Figure 1) by validated 
quantitative-PCR methods in two cohort of NSCLC 
patients treated with platinum/gemcitabine-based regimens 
and we correlated gene expression levels with response to 
treatment and outcome.
RESULTS
Treatment efficacy
 Fifty-eight patients with locally advanced or 
advanced disease were treated with a platinum/gemcitabine 
regimen for at least 2 cycles (Table 1). Before entering 
the study, the patients of this cohort (named “test cohort”) 
were subjected to a radiological evaluation by means 
of a CT scan, which was repeated after 2 or 3 cycles of 
chemotherapy in order to assess the tumor response rate. 
A radiological response evaluation was possible 
for all patients enrolled. Of the 58 evaluable patients, 
one patient (1.7%) had a complete response, 28 (48.3%) 
showed partial response, 18 (31.1%) had stable disease, 
while 11 patients (19%) experienced disease progression 
(Table 2). 
Cut-off values for each of the clinical and 
pathological factors were selected according to the median 
value for continuous variables, and univariate analysis was 
carried out to identify those factors significantly associated 
with outcome. Surprisingly, these analyses showed that 
those patients obtaining CR/PR were significantly older 
than patients with SD or PD (p = 0.030). Conversely, sex 
(p = 0.387), stage (p = 0.390), histology (p = 0.692) and 
chemotherapy (i.e., the chemotherapy regimens included, 
in addition to gemcitabine, either carboplatin or cisplatin) 
(p = 0.572) were not significantly associated with response.
Gene expression levels according to response to 
platinum-gemcitabine therapy
To find out whether the different gene expression 
could be correlated to an objective response to platinum-
gemcitabine chemotherapy, we evaluated the expression 
levels of dCK, cN-II, CDA, RRM1, RRM2, hENT1 
and ERCC1 by quantitative-PCR, in those patients who 
achieved a measurable RECIST response (responders, 
CR or PR) compared to patients who had stable disease or 
disease progression (non-responders, SD or PD). mRNA 
Figure 1: Key determinants of gemcitabine and platinum chemosensitivity/resistance. Black lines, metabolism; Red lines, 
targets of the activity. Abbreviations: dFdCDP, gemcitabine diphosphate; dFdCMP, gemcitabine monophosphate; dFdCTP, gemcitabine 
triphosphate; dFdU, 2’,2’-difluoro-deoxyuridine.
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levels were normalized to either β-actin or GAPDH. The 
results showed comparable means and variability in the ratio 
of each target gene with the two different housekeeping 
genes (Figure 2 and Supplementary Figure 1). 
Expression levels of all the studied genes were not 
associated with any of the clinical-pathological factors 
considered above. 
The plot in Figure 2 shows the distribution of 
gene expression levels normalized to β-actin according 
to tumor response. The observed variability suggests 
a possible stratification of patients in order to create 
homogeneous groups with different likelihoods of 
response to treatment. By adopting cut-off values 
according to median expression levels, and using 
β-actin as housekeeping gene, cN-II was the only gene 
that reached statistical significance for differential 
expression between the responder and non-responder 
patients, with lower levels in those patients achieving 
a better RECIST response (p = 0.016; Table 3 and 
Figure 2). Interestingly all markers but dCK and hENT1 
were homogenous in terms of variability, with a CV% 
ranging from 5.0% (cN-II CR/PR and ERCC1 CR/
PR) to 8.1% (CDA overall) (Table 3). The potential 
use of the median value of cN-II as a predictor of 
clinical outcome was also suggested by using GAPDH 
as housekeeping gene, but this was not statistically 
significant (Supplementary Figure 1). 
In the univariate logistic regression analysis, 
we observed a possible “dose-response” relationship 
between the cN-II expression levels and the risk 
(odds-ratio) of non-response (Figure 3): the higher the 
expression level, the higher the odds of non-response. 
Indeed by using the 25th, 50th (median) and 75th 
percentiles as cN-II mRNA cut-off levels, we estimated 
the odd-ratio of 1.48, 5.16 and 6.90 (p = 0.56, p = 0.08, 
p = 0.023) respectively. Furthermore in the multivariate 
analysis, cN-II expression still remained a significant 
predictive factor, with the risk of non-response increasing 
up to 6.10 times (p = 0.047) for cN-II expression levels 
above median (Table 4).
Table 1: Patient characteristics of the test and validation cohorts
Characteristics Test cohort Validation cohort
Age at Diagnosis
mean ± sd (median)
min, max
61.8 ± 8.5 (61.9)
40, 78
63.5 ± 6.6 (63.1)
50, 78
Gender, no. (%)
Female
Male
17 (29.3)
41 (70.7)
11 (27.5)
29 (72.5)
Histology, no. (%)
NSCLC* 27 (46.6)
SCC   6  (10.3) 17 (42.5)
ADK 24 (41.4) 22 (55.0)
Large Cells   1 (1.7) 1 (2.5)
Stage, no. (%)
IIIA 43 (74.1) 0 (0)
IIIB 7 (12.1) 18 (45.0)
IV 8 (13.8) 22 (55.0)
*The morphology was poorly specified and these patients were defined NSCLC.
Table 2: Response to treatment of the patients in the test and validation cohorts         
Chemotherapy cycles
mean ± sd (median)
min, max
3.4 ± 1.0 (3.0)
2, 6
4.5 ± 1.3 (4.0)
2, 6
Responses, no. (%)
CR  1  (1.7) 0 (0.0)
PR 28 (48.3) 14 (35.0)
SD 18 (31.0) 20 (50.0)
PD 11 (19.0) 6 (15.0)
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Gene expression levels of cN-II according to 
survival in the test and validation cohort
Despite the limited number of patients in 
advanced stage, we evaluated whether the expression 
of cN-II correlated with overall survival (OS). As 
shown in the Figure 4A, patients with “high” expression 
have an OS of 19.3, compared to 26.5 months of the 
patients with “low” cN-II expression (p = 0.1038). 
However, we performed further analyses in a validation 
cohort, including advanced stage patients, treated with 
gemcitabine-cisplatin, as described previously [32, 
33]. The characteristics and response of these patients 
are described in the Tables 1 and 2. In these patients, 
by using the median of cN-II mRNA cut-off level, 
the “high” expression correlated with a significantly 
increased risk of non-response (p = 0.034). Moreover, 
the progression-free survival (PFS) and OS were 
significantly longer in patients with “low” cN-II 
expression (Figure 4B–4C).
Modulation of gemcitabine antiproliferative 
effects
The quantitative-PCR evaluation of cN-II in three 
NSCLC cells showed expression levels similar to those 
detected in tumor specimens, ranging from 1.083 (A549 
cells) to 1.056 (H292 cells). To assess whether the down-
regulation of cN-II gene expression similar to the gene 
expression variability detected in the lung tissues might 
affect the cytotoxic activity of gemcitabine, we performed 
specific experiments with siRNA gene silencing against 
cN-II. The negative-control siRNA did not affect cN-II 
expression; while we observed a significant reduction of 
cN-II levels after transfection with 5 nmol siRNA for cN-
II (Figure 5A). Importantly, the down-regulation of cN-II 
was associated with increased sensitivity to gemcitabine, as 
demonstrated by the significant reduction in the percentages 
of cell viability (Figure 5B).
Similarly, pharmacological experiments testing the 
combination with the cN-II inhibitor DEPC showed a 
Figure 2: Gene expression levels according to clinical response normalized to β-actin. Boxplots distribution of data: the 
edges of each box indicate the 25th (bottom) and 75th (top) percentiles. The marker and the line inside the box are the mean and the median 
value respectively. The whiskers indicate values close enough to the box not to be considered outliers. Other points are considered to be 
outliers.
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decrease of the IC50 values of gemcitabine, as shown by 
the significantly shifted dose response curves in the A549 
and H1703 cells (Figure 5C).
DISCUSSION
Platinum compounds and gemcitabine are widely 
used to treat NSCLC patients in different settings of 
disease and it is of paramount importance to identify 
predictive biomarkers that could be easily assessed in daily 
practice to select those patients who can most benefit from 
these cytotoxic agents. This study evaluated the expression 
of several key genes involved in the regulation of the 
activity and metabolism of platinum and gemcitabine 
in microdissected, frozen NSCLC specimens, and, to 
our knowledge, is the first to demonstrate a significant 
association of cN-II mRNA levels with response to 
platinum and gemcitabine in advanced NSCLC patients. 
One main strength of this study is that gene 
expression was assessed by a validated PCR method in 
frozen specimens, that were laser-microdissected to avoid 
the contamination of normal cells surrounding the tumor. 
Specimens were obtained by various methods and from 
various sites, including metastatic lymph nodes. However, 
in our previous study in 88 laser-microdissected samples 
from NSCLC patients we did not observe a significant 
difference between primary tumor and tumor metastasis, 
supporting the use of both lymph nodes and primary 
tumors for the expression profiling of NSCLC [14].
Moreover, we used two different housekeeping 
genes, GAPDH and β-actin, to improve the reliability of 
the results. Interestingly, the pattern of gene expression 
was comparable with both the housekeeping genes, even 
if the role of cN-II as a predictor of platinum-gemcitabine 
efficacy showed only a trend toward statistically 
significant difference, with GAPDH. However, the 
utility of GAPDH as a good reference sequence has been 
criticized since human genome contains many GAPDH 
pseudogenes which have identical or nearly identical 
sequences to the active, target GAPDH transcript, and 
therefore primers or probes spanning exon junctions will 
detect the presence of the pseudogenes along with the 
cDNA of the active transcript [34]. 
The main objective of this study was to assess 
the correlation of gene expression with tumor response. 
Indeed, RECIST tumor evaluation gives objective 
information on drug activity, without being influenced by 
other variables, including further treatment lines, which 
can instead influence overall survival. Furthermore, the 
identification of genes that could predict a reduction 
Table 3: Summary statistics of β-actin normalized gene-expression according to response
Marker Response No. Mean ± SD Median CV% p (*)
dCK
Overall 52 1.035 ± 0.020 0.986 14.2
CR/PR 25 1.025 ± 0.030 0.974 14.8 0.410
SD/PD 27 1.044 ± 0.028 1.016 13.8
cN-II
Overall 49 1.072 ± 0.010 1.074 6.7
CR/PR 25 1.058 ± 0.011 1.053 5.0 0.016
SD/PD 24 1.087 ± 0.018 1.092 8.0
CDA
Overall 52 1.103 ± 0.012 1.106 8.1
CR/PR 25 1.083 ± 0.017 1.079 7.9 0.410
SD/PD 27 1.121 ± 0.018 1.119 8.1
RRM1
Overall 47 1.053 ± 0.008 1.046 5.4
CR/PR 22 1.047 ± 0.012 1.034 5.2 0.110
SD/PD 25 1.058 ± 0.012 1.068 5.6
RRM2
Overall 44 1.083 ± 0.010 1.062 6.4
CR/PR 22 1.075 ± 0.013 1.060 5.5 0.074
SD/PD 22 1.091 ± 0.017 1.085 7.2
hENT1
Overall 50 1.033 ± 0.018 1.030 12.3
CR/PR 25 1.027 ± 0.021 1.021 10.2 0.401
SD/PD 25 1.039 ± 0.030 1.042 14.2
ERCC1
Overall 50 1.025 ± 0.008 1.017 5.6
CR/PR 24 1.018 ± 0.010 1.018 5.0 1.000
SD/PD 26 1.030 ± 0.012 1.017 6.2
(*) CR/PR vs. SD/PD comparison. Wilcoxon two-sample two-sided test or unpaired t-test as appropriate
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in tumor size could be particularly relevant in the 
neoadjuvant setting, where platinum/gemcitabine regimen 
is also widely used. We observed an inverse correlation 
between cN-II mRNA levels and response to a platinum-
gemcitabine treatment, as detected using the 25th, 50th 
(median) and 75th percentiles as cut-off levels, with lower 
cN-II expression associated to a better RECIST response. 
Its role as a predictor of platinum-gemcitabine efficacy 
was confirmed also in multivariate analysis, with a risk 
of non-response increased up to 6 times for cN-II levels 
above median. Despite the patient number of advanced 
stage was very small, we also observed a trend toward 
increased survival in patients with low cN-II expression. 
However, we observed a significant correlation between 
cN-II expression and both PFS and OS in an independent 
validation cohort of stage IIIB/IV patients. 
This cytoplasmic nucleotidase is a key enzyme 
involved in gemcitabine inactivation, but can also affect 
the metabolism and activity of other nucleoside analogues, 
including fludarabine, cytarabine and cladribine. Several 
studies have correlated the expression of cN-II to clinical 
outcome to treatment with nucleoside analogues in 
patients with hematological malignancies and solid tumors 
[35]. A high cN-II activity was observed in resistant 
chronic lymphocytic leukaemia patients treated with 
cladribine [36], as well as in human acute T lymphoblastic 
leukaemia cells [30]. Regarding NSCLC, Sève et al. 
assessed the protein abundance of cN-II, hENT1, the 
human concentrative nucleoside transporter-3 (hCNT3) 
and dCK by immunohistochemistry (IHC), in tumors of 
patients with locally or advanced disease, treated with 
gemcitabine, and correlated it with clinical outcome [23]. 
Figure 3: Univariate odds ratios of getting a SD/PD by gene expression marker quantiles. A Forest plot type showing the 
odds-ratios of getting a SD/PD for gene expression marker values greater than a given percentile. The bars represents the 95% confidence 
intervals around the odds-ratio, the dot is the point estimate of the odds-ratio.
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Table 4: Multivariate Odds-ratios of getting a SD/PD according to β-actin normalized gene-expression marker’s 
median levels (Low vs. High expression)
Status
No. (col %)
Marker Odds-Ratio 95% CI p (*)
dCK Low 1
High 1.95 0.34, 11.2 0.454
cN-II Low 1
0.047High 6.10 1.02, 36.5
CDA Low 1
High 0.93 0.14, 5.98 0.936
RRM1 Low 1
High 1.12 0.17, 7.43 0.909
RRM2 Low 1
High 3.48 0.76, 16.1 0.109
hENT1 Low 1
High 0.59 0.10, 3.61 0.564
ERCC1 Low 1
High 0.42 0.08, 2.17 0.298
(*) Wald Chi-square test.
Figure 4: Survival and progression-free survival curves. Overall survival (OS) and progression-free survival (PFS) curves 
segregated according to cN-II mRNA expression levels in the NSCLC patients from the test (A) and validation cohort (B, C). High/low 
levels are relative to the median values acquired by quantitative-PCR data in laser-microdissected samples available from the patients of 
the two cohorts. The curves were compared using the log-rank test. 
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Among the 43 samples analyzed, 36 (86%) expressed cN-
II and this was the only protein associated with overall 
survival, while no association was found with response. 
This apparent difference with our results could be due to 
the different methods used for measuring cN-II levels. 
Indeed, no information is available about the correlation 
between cN-II mRNA levels, as measured by quantitative-
PCR, and protein expression detected by IHC. In order to 
correlate cN-II protein expression with tumor reduction, we 
performed cN-II IHC analysis as well. Unfortunately, cN-II 
staining (monoclonal antibody against cN-II clone ECNII) 
was not successful in our study samples (data not shown). 
To evaluate whether modulation of gene expression 
similar to the gene expression variability detected in the lung 
tissues might affect the cytotoxic activity of gemcitabine, 
we performed specific experiments with siRNA gene 
silencing against cN-II in three NSCLC cell lines. In these 
experiments, we observed expression differences comparable 
Figure 5: Increased activity of gemcitabine by silencing or pharmacological inhibition of cN-II in NSCLC cell lines. 
(A) Quantitative RT-PCR analysis of cN-II mRNA expression in NSCLC cell lines. Results are presented relative to the expression levels 
of β-actin and show that silencing with a specific siRNA for cN-II (siRNA-cN-II) significantly reduced the expression of cN-II compared 
to cells treated with the siRNA tranfection reagents, named “siRNA solvent”, in all the three cell lines. (B) Cell growth of cells treated with 
gemcitabine (at the cell line specific IC50) after exposure to siRNA-cN-II. Cell growth of treated cells was compared to growth of untreated 
control cells set at 100%. (C) Representative curves of growth inhibitory effects of gemcitabine and of the simultaneous combination of 
gemcitabine and of the cN-II inhibitor DEPC in H1703 and A549 cells. The IC50 values were significantly reduced in both cell lines. 
Similar results were obtained in the H292 cells (data not shown). Points and columns, mean values obtained from three independent 
experiments; bars, S.E. *Significantly different from (P < 0.05) from respective controls (“siRNA solvent”).
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with those detected in the clinical samples, and cytotoxicity 
assays showed that down-regulation of cN-II caused a 
significant increase of gemcitabine sensitivity. As negative-
control siRNA, which did not affect cN-II expression, 
did not alter the cell growth, these results indicate that the 
modulation of gemcitabine cytotoxicity was determined by 
the specific perturbation of the expression of cN-II. Further 
experiments showed a significant decrease of the IC50 
values of gemcitabine after simultaneous treatment with 
gemcitabine and the cN-II inhibitor DEPC. These results 
are in agreement with previous studies showing increased 
sensitivity to gemcitabine after treatment with DEPC in 
pancreatic, lymphoid and lung cancer cell lines [37–39]. 
We can therefore hypothesize that this knowledge could be 
translated also for other tumor types where gemcitabine alone 
or the combination of gemcitabine/cisplatin is used, such as 
cholangiocarcinomas or urinary tract cancers [40, 41].
It is well recognized that the presence of single 
nucleotide polymorphisms (SNPs) in crucial genes 
involved in drug metabolism can influence the expression 
or functions of corresponding proteins, thus contributing 
to inter-individual variability in response and clinical 
outcome to specific classes of cytotoxic drugs. Indeed, 
recent studies in lymphoblastoid cell lines with the 
common polymorphism rs2274341 in the cN-II had lower 
cN-II expression and cytarabine sensitivity [42] and the 
presence of this polymorphism in lung cancer patients 
treated with gemcitabine was significantly associated with 
a better survival [42, 43]. We can therefore hypothesize 
that the presence of single nucleotide polymorphisms 
(SNPs) of the cN-II gene might affect also clinical 
response by modulating cN-II expression, and further 
studies on these SNPs are warranted.
The expression of cN-II might be influenced by several 
other factors. In particular, some recent studies suggested 
the key role of microRNA (miRNA) in the regulation on 
key determinants of chemotherapeutic drugs activity [44]. 
According to the miRTarBase database a total of 62 miRNAs 
might target cN-II, but only 6 miRNAs were validated in 
next-generation sequencing studies in more than two articles, 
as described in the Supplementary Table 1.
We also assessed RRM1 and ERCC1, whose high 
expression has been shown to correlate with resistance in 
advanced NSCLC patients treated with gemcitabine and 
platinum in a number of retrospective studies [24–27, 17, 18]. 
However, no prospective trials have validated their role in 
customizing systemic therapy [45, 46, 17]. Also, in our study 
we did not find any correlation between ERCC1 or RRM1 
mRNA expression and clinical response to treatment. 
These results are limited by the small sample size 
in each cohort. Two other important limitations of the 
present study are that the p values were not corrected for 
multiple hypotheses, and that the significant correlation 
of cN-II levels was demonstrated under very specific 
conditions, namely, by use of the median as a cut off and 
with normalization of mRNA expression levels according 
to only one housekeeping expression pattern.
In conclusion, cN-II expression emerged as the only 
predictor of responsiveness to treatment with gemcitabine 
and platinum. These results suggest a potential prognostic/
predictive value of cN-II and should prompt further 
validation in prospective studies in larger cohorts of 
patients, that will be crucial to demonstrate whether 
cN-II could be useful in the clinical setting to personalize 
chemotherapy in NSCLC patients.
MATERIALS AND METHODS
Patient characteristics
From 2004 to 2008, a total of 58 chemotherapy-
naive patients affected by locally advanced or metastatic 
NSCLC were treated with a platinum/gemcitabine-based 
combination regimen at the European Institute of Oncology 
and were enrolled in our study. Characteristics of patients 
are shown in Table 1. In summary, there were 17 women 
and 41 men, with age at diagnosis ranging from 40 to 78 
years. Forty-three patients had stage IIIA disease, 7 stage 
IIIB and 8 stage IV disease.
Before initiating neo-adjuvant or first-line 
chemotherapy, patients were subjected to tumor biopsy, 
including bronchoschopy (1/58), mediastinoscopy (41/58), 
minithoracotomy (2/58), supraclavicular lymph node biopsy 
(7/58), video-assisted thoracoscopy (5/58) or liver biopsy 
(2/58) with collection of fresh tumor specimens. Gene 
expression analyses were performed in one (1.7%) sample 
from the primary tumor, 50 (86.2%) from metastatic lymph 
nodes and 7 (12.1%) from distant metastases.
All the patients received a standard platinum-
based treatment (46 patients received cisplatin and 12 
carboplatin) in association with gemcitabine, for at least 
2 cycles. Assessment of tumor response was carried out 
by computed tomography (CT) scan every two or three 
cycles. Responses were assessed by using Response 
Evaluation Criteria in Solid Tumors (RECIST). [47].
All patients gave written informed consent. The study 
was approved by the local Institutional Ethics Committees 
and was conducted in accordance with Good Clinical 
Practice guidelines and the Declaration of Helsinki.
Independent validation cohort 
Further studies on the correlation of the expression 
of cN-II with clinical outcome were performed in 
laser-microdissected specimens from an independent 
validation cohort of 40 chemotherapy-naïve patients 
with histologically or cytologically proven NSCLC and 
measurable clinical stage IIIB or IV disease from Livorno 
Civil-Hospital (Livorno, Italy). Eighteen patients had 
stage IIIB and 22 stage IV disease. All these patients were 
subjected to tumor biopsy, and then received chemotherapy, 
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which consisted of cisplatin 80 mg/m2 infused over 
60 minutes on day-1 and gemcitabine 1,200 mg/m2 
administered intravenously over 30 minutes on day-1 and 
8, every 3 weeks for a maximum of 6 courses. Treatment 
was discontinued in case of progression, major toxicities, or 
according to the patient’s or physician’s decision. 
Sample collection and processing
 Frozen tissue sections (5 μm) were thawed, fixed 
in 75% ethanol, and dehydratated in 100% ethanol and 
xylene. Neoplastic cells were then dissected using the laser 
microdissector Leica AS/LMD (Leica, Wetzlar, Germany). 
Laser-captured cells were pooled in lysis buffer and RNA 
was extracted with the QIAamp RNA Mini kit (Qiagen, 
San Diego, CA, USA). RNA was dissolved in DNase/
RNase-free water, and measured by absorbance reading 
at 260/280 nm. RNA yields and integrity were checked at 
260–280nm with NanoDrop®-1000-Detector (NanoDrop-
Technologies, USA).
Quantitative-PCR analysis
From 50 to 500 ng RNA was reverse-transcribed. 
The resulting cDNA was amplified with the 7900HT 
sequence detection system (Applied Biosystems, Foster 
City, CA, USA). Forward and reverse primers and 
probes were designed with Primer Express 2.0 (Applied 
Biosystems) based on dCK (NM_000788), cN-II 
(NM_012229), and CDA (NM_001785) gene sequence 
obtained from the GenBank, whereas primers and probes 
for RRM1 (NM_001033), RRM2 (NM_001034), hENT1 
(NM_004955) and ERCC1 were obtained from Applied 
Biosystems Assay-on-Demand products (Hs00168784, 
Hs0035724, Hs00191940 and Hs01012158). Validation 
experiments were carried out with cDNA obtained from 
QPCR Human Reference Total RNA (Stratagene, La Jolla, 
CA, USA), as described previously [48, 49]. Specimens 
were amplified in triplicate with appropriate nontemplate 
controls, and the coefficient of variation was <2% for all 
replicates. 
Effects of inhibition of cN-II on gemcitabine 
cytotoxicity
To investigate whether the gene expression 
variability of cN-II observed between tumor tissues might 
affect the cytotoxic activity of gemcitabine, we evaluated 
the effects of a specific siRNA (Assay ID#36451, 
ThermoFisher Scientific, Waltham, MA, USA) against 
cN-II in three NSCLC cell lines (A549, H292 and H1703) 
characterized by high, intermediate and low cN-II mRNA 
levels, as assessed by quantitative-PCR.
Cells were plated at 105 cells per well in 6-well 
plates and, after 24 hours, were transfected with small 
interfering RNA (siRNA) oligonucleotide or negative-
control siRNA using Oligofectamine (Invitrogen) to result 
in a final RNA concentration of 5 and 25 nmol/l in serum-
free medium, according to the manufacturer’s instructions. 
After 24 hours, the cells were treated with gemcitabine 
(0.01–500 nM) for 48 hours, while RNA was extracted 
from parallel wells, using the TRI REAGENT LS (Sigma-
Aldrich).  At the end of drug treatment, the cell growth 
inhibitory effect of gemcitabine was studied by direct 
cell count using the trypan blue. Growth inhibition was 
expressed as the percentage of gemcitabine-untreated 
controls (untransfected and negative-control siRNA-
treated cells), and the 50% inhibitory concentration of cell 
growth (IC50) was calculated by non-linear least squares 
curve fitting (GraphPad PRISM, Intuitive Software for 
Science, San Diego, CA, USA). 
Additional pharmacological studies were performed 
with the cN-II inhibitor diethylpyrocarbonate (DEPC). Cells 
were plated in 96-well plates, and treated with gemcitabine 
for 72 hours alone or in combination with 10 μM DEPC. 
The cell growth inhibitory effects were studied using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) 
assay. IC50 values were calculated as described above. 
Statistical analyses
Demographic and clinical information were 
obtained from medical records. Summary statistics (n, 
mean, standard errors, median and CV%) for all gene 
expression normalized either to GAPDH or β-actin by 
clinical response, as well as by pathological response and 
overall survival (OS) were either tabulated or box-plotted. 
Factors included in the univariate analysis were sex, age 
at diagnosis, clinical stage and histology. 
Comparison between gene expression levels and 
clinical response (complete response, CR, or partial 
response, PR, defined according to RECIST criteria), 
as well as for stable disease (SD) + progressive disease 
(PD) and other class-levels of clinico-pathological factors 
were performed using Fisher’s exact two-sided test, 
Kruskal–Wallis test, median test or unpaired Students 
t-test as appropriate (Satterthwaite method was adopted 
for unequal variances as tested by the Folded F method). 
Normality was tested using the Shapiro–Wilk test. 
Univariate and multivariate logistic regressions were 
carried out to determine the association between gene 
expression and therapy responsiveness, calculating the 
crude and adjusted odds ratio (OR) with 95% confidence 
intervals (CI) using the first, second and third quartiles 
of the gene expression distributions. Lower quartiles were 
used as reference category. The level of significance was 
set at 5%, all test were two-sided. The Kaplan–Meier 
method was used to plot overall survival, and the log-rank 
test was used to compare curves in univariate analysis. 
Data were analyzed using SAS 9.2 (Cary, NC, USA) and 
STATA/SE 11.1 (StataCorp., TX, USA). 
All in vitro experiments were performed in triplicate 
and were repeated at least three times. Data were expressed 
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as mean values S.E. and were analyzed by Student’s t test 
or analysis of variance followed by the Tukey’s multiple 
comparisons; the level of significance was set at P < 0.05. 
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